Summary:
- Novartis, a leading pharmaceutical company, has received approval for the first malaria medicine specifically designed for newborn babies and young infants.
- This new treatment, called Coartem Dispersible, is a dispersible tablet formulation of the antimalarial drug artemether-lumefantrine, which is effective in treating uncomplicated malaria in infants and children.
- The approval of this child-friendly malaria medicine is a significant step forward in addressing the high burden of malaria in young children, particularly in sub-Saharan Africa, where the disease is a leading cause of death.